Lv21
158 积分 2026-01-03 加入
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
45分钟前
待确认
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
1个月前
已完结
Interacting partners regulate PIEZO channel force sensing
1个月前
已完结
Complete and Prolonged Response to Immune Checkpoint Blockade in POLE-Mutated Colorectal Cancer
1个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
2个月前
已完结
A panoply of errors: polymerase proofreading domain mutations in cancer
2个月前
已完结
Targeting GAS6/AXL signaling improves the response to immunotherapy by restoring the anti-immunogenic tumor microenvironment in gastric cancer
2个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
2个月前
已完结
KEAP1-mediated mitochondrial remodeling on stiffness-graded collagen substrates drives hepatocellular carcinoma adaptation
3个月前
已完结
Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy
4个月前
已完结
皖公网安备34019202002308
